Chugai Seiyaku Kabushiki Kaisha

Chugai Seikayu Kabushiki Kaisha

Hiromitsu Kawata

Haruhiko Sato

Takuya Shiraishi

Hitoshi Yoshino

Masateru Ohta

Kazutaka Tachibana

Mitsuaki Nakamura

Ikuhiro Imaoka

Masahiro Nagamuta

Takashi Emura

Minoru Machida

Teruo Nakamura

Hajime Miyamoto

Yasuo Sekimori

Etsuro Onuma

Kenji Taniguchi

Akie Honma

Kazutaka c/o Chugai Seiyaku Kk Tachibana

Haruhiko c/o Chugai Seiyaku Kk Sato

Takuya c/o Chugai Seiyaku Kk Shiraishi

Mitsuaki c/o Chugai Seiyaku Kk Nakamura

Hitoshi c/o Chugai Seiyaku Kk Yoshino

Ikuhiro c/o Chugai Seiyaku Kk Imaoka

Masateru c/o Chugai Seiyaku Kk Ohta

An imidazole derivative represented by formula (I): wherein Q is: A is hydrogen, halogen, or a substituted or unsubstituted Calkyl group; E is independently selected from a Calkyl group; Rand Rare independently selected from Calkyls; Xand Xare independently selected from O and S; Y is selected from a substituted or unsubstituted arylene group and a substituted or unsubstituted divalent 5- or 6-membered monocyclic or 8- to 10-membered condensed heterocyclic group; Z is &#x2014;CON(&#x2014;Ra)&#x2014;, &#x2014;CO&#x2014;, &#x2014;OOO&#x2014;, &#x2014;NRa&#x2014;C(&#x2550;NH)NRb&#x2014;, &#x2014;NRa&#x2014;C(&#x2550;N&#x2014;CN)NRb&#x2014;, &#x2014;N(&#x2014;Ra)COO&#x2014;, &#x2014;C(&#x2550;NH)&#x2014;, &#x2014;SO&#x2014;, &#x2014;SON(&#x2014;Ra)&#x2014;, &#x2014;SONR&#x2014;, &#x2014;N(&#x2014;Ra)CO&#x2014;, &#x2014;N(&#x2014;Ra)CON(&#x2014;Rb)&#x2014;, &#x2014;N(COR)CO&#x2014;, &#x2014;N(&#x2014;Ra)SO&#x2014;, &#x2014;N(SOR)SO&#x2014;, &#x2014;N(&#x2014;Ra)&#x2014; or &#x2014;N(&#x2014;Ra)SON(&#x2014;Rb)&#x2014;; Ris independently a hydrogen atom, a hydroxyl group, or substituted or unsubstituted group selected from Calkyl group, heterocyclic group, aryl group, Ccycloalkyl group and Ccycloalkenyl group; or salt or prodrug thereof.

Imidazolidine derivative and use thereof

The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a need to develop a PEG-conjugated EPO with significantly sustained efficacy by introducing a controlled number of PEG molecules at controlled positions. This PEG-conjugated EPO addresses such a need and provides more sustained efficacy.

PEG-conjugated erythropoietin

The present invention provides a compound represented by formula (I):  A is cyano or the like; B is hydrogen, halogen, or the like; Xand Xare each independently selected from O and S; E is a Calkyl group; and R, R, Rand Rare each independently selected from a hydrogen atom and a C-Calkyl group, and a drug, a pharmaceutical composition containing the compound, and the like.

Imidazolidine derivatives

The present invention provides a compound represented by formula (I): [Formula 1] wherein n is an integer selected from 1 to 20, and Rand R, which may be the same or different, each represent a hydrogen atom, or a linear or branched C-Calkyl group, or a salt, a prodrug or a solvate thereof, as well as a drug, a pharmaceutical composition containing the compound, and the like.

Growing community of inventors

Kamakura, Japan

Hiromitsu Kawata